Ateganosine

Ateganosine
Clinical data
Other names2'-Deoxythioguanosine
Identifiers
  • 2-amino-9-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3H-purine-6-thione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC10H13N5O3S
Molar mass283.31 g·mol−1
3D model (JSmol)
  • C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2NC(=NC3=S)N)CO)O
  • InChI=InChI=1S/C10H13N5O3S/c11-10-13-8-7(9(19)14-10)12-3-15(8)6-1-4(17)5(2-16)18-6/h3-6,16-17H,1-2H2,(H3,11,13,14,19)/t4-,5+,6+/m0/s1
  • Key:SCVJRXQHFJXZFZ-KVQBGUIXSA-N

Ateganosine is a telomerase inhibitor[1] and apoptosis inducer currently under investigation for the treatment of various cancers, including non-small cell lung cancer (NSCLC).[2]

References

  1. ↑ Eglenen-Polat B, Kowash RR, Huang HC, Siteni S, Zhu M, Chen K, et al. (January 2024). "A telomere-targeting drug depletes cancer initiating cells and promotes anti-tumor immunity in small cell lung cancer". Nature Communications. 15 (1) 672. Bibcode:2024NatCo..15..672E. doi:10.1038/s41467-024-44861-8. PMC 10803750. PMID 38253555.{{cite journal}}: CS1 maint: unflagged free DOI (link)
  2. ↑ "Ateganosine". PatSnap.


This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.